ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q3 2025 Earnings Call Transcript
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q3 2025 Earnings Call Transcript November 10, 2025ARS Pharmaceuticals, Inc. misses on earnings expectations.
Ars Pharmaceuticals Inc. (SPRY)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 10,860,977 | $109,152,819 | 1.34% | |
| 2. | OrbiMed Advisors Samuel Isaly | 8,288,510 | $83,299,526 | 1.96% | |
| 3. | Deerfield Management James E. Flynn | 7,503,812 | $75,413,311 | -23% | 1.15% |
| 4. | Rubric Capital Management David Rosen | 4,500,000 | $45,225,000 | +248% | 0.51% |
| 5. | SR One Capital Simeon George | 4,012,903 | $40,329,675 | 5.83% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.79 | 505,954 | $4,953,289.66 | 9,958,073 | 2024-03-27 | Filing | |
| $9.55 | 457,745 | $4,371,464.75 | 9,452,119 | 2024-03-26 | Filing | |
| $9.06 | 437,600 | $3,964,656.00 | 8,994,374 | 2024-03-25 | Filing | |
| $3.78 | 46,258 | $174,994.01 | 89,227 | 2023-09-29 | Filing | |
| $3.62 | 40,000 | $144,960.00 | 42,969 | 2023-09-28 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.71 | 21,828 | $190,049.85 | 10,789 | 2025-11-13 | Filing | |
| $8.86 | 136,380 | $1,208,790.49 | 0 | 2025-11-12 | Filing | |
| $8.91 | 30,000 | $267,357.00 | 136,380 | 2025-11-12 | Filing | |
| $14.49 | 50,000 | $724,345.00 | 1,196,494 | 2025-08-21 | Filing | |
| $15.00 | 12,500 | $187,500.00 | 10,042 | 2025-08-21 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,831,327 | $48,554,836 | 0% | |
| 2. | 3,500,303 | $35,178,046 | 0% | |
| 3. | 3,097,022 | $31,125,071 | 0.05% | |
| 4. | 2,895,256 | $29,097,323 | 0% | |
| 5. | 2,642,111 | $26,553,216 | 0.01% |
News See All
ARS Pharmaceuticals, Inc. (SPRY): A Bull Case Theory
We came across a bullish thesis on ARS Pharmaceuticals, Inc. on Value Degen’s Substack’s Substack by Unemployed Value Degen. In this article, we will summarize the bulls’ thesis on SPRY.
ARS Pharmaceuticals (SPRY) Faces Patent Test as Lupin Files ANDA
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is among the fastest growing small cap stocks to buy.
11 Fastest Growing Small Cap Stocks to Buy
These days, everyone is obsessed with speed: fast fashion, fast food, fast internet.
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q2 2025 Earnings Call Transcript
Operator: Good morning and welcome to the ARS Pharmaceuticals Conference Call. [Operator Instructions] Please be advised today's conference is being recorded.
Jim Cramer on ARS Pharmaceuticals: “It's a Great Flier”
ARS Pharmaceuticals (NASDAQ:SPRY) is a biopharmaceutical company focused on helping patients and caregivers manage severe allergic reactions, with its product neffy, a nasal epinephrine spray approved...
Jim Cramer Discussed These 16 Stocks Recently
“It's all coming together for the most speculative stocks in the market, and it's a dream come true for many dreamers… It's the year of magical thinking… and boy is that year ever paying off.
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q1 2025 Earnings Call Transcript
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q1 2025 Earnings Call Transcript May 14, 2025ARS Pharmaceuticals, Inc. reports earnings inline with expectations.
10 Unstoppable Stocks That Could Double Your Money
Generating significant returns and multiplying their money in the stock market remains a primary goal for most investors.
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q4 2024 Earnings Call Transcript
Operator: Good day, and welcome to ARS Pharmaceuticals Fourth Quarter and Full Year 2024 Financial Results Conference Call. At this time all participants are in listen-only mode.